reptides › healing › thymosin α-1

thymosin α-1

thymic immune peptide. approved abroad for hepatitis B. used stateside for generic 'immune support.'

tier B · healing · global Zadaxin · 35 markets

verdict

thymic immune peptide. approved abroad for chronic hepatitis B adjunct. used stateside for off-label 'immune support' on much thinner data.

if you're asking about chronic hepatitis B adjunct use — this is the strongest evidence lane. approved in ~35 countries, decades of clinical use, clean safety profile. the indication abroad is real. the rest of the chronic-viral and oncology literature is weaker and more mixed. Ciancio 2012 in HCV retreatment was negative, and the larger sepsis story has weakened post-TESTS (2025, n=1,106, BMJ) which missed its primary 28-day mortality endpoint (23.4% vs 24.1% placebo).

if you're asking about generic 'immune support' / long COVID / chronic fatigue — this is the way the US peptide community actually uses it, and the trial base for these uses is just extrapolation. modest but consistent reports from users with documented immune dysregulation. healthy users tend to report less, which is what immunomodulators should do. the Dec 4, 2024 FDA PCAC voted against 503A inclusion (after the nominator withdrew in Sept 2024), effectively closing the US compounded-pharmacy pathway.

if you came in via the immunotherapy combination story — the 2025 HCC retrospective (Tα1 + lenvatinib + sintilimab) showed real survival signal as immunotherapy adjunct. median OS 16 vs 11 months. that's the live frontier. immunosenescence and PD-1 combination work is where modern literature is drifting. the gap between this oncology-adjunct frontier and 'I bought a vial for general immune support' is wide.

based on published evidence and disclosed clinical practice. not medical advice.

why B-tier

B-tier reflects an unusual strength: thymosin alpha-1 has more real human evidence than almost anything near this grade. Multiple RCTs, several meta-analyses, approval as a genuine drug in more than 35 countries, and a clean decades-long safety record. The on-label hepatitis B adjunct data are real, and the one Cochrane-proven benefit, fewer serious infections during chemotherapy and radiation, is real. That drug-grade human evidence earns the B. What keeps it off A is two-fold: where it was tested rigorously and broadly the big modern trials came back null (the TESTS sepsis trial, three failed hepatitis C Phase 3 trials, the melanoma trial that missed survival, mixed acute-COVID data), and the grey market buys it for indications with essentially no human evidence (long COVID, ME-CFS, general 'immune support'). It is not a C: the evidence here is real, deep, and drug-grade, not thin. It is a strong drug whose proven wins are narrow and whose community use runs ahead of the evidence.

the core tension

Thymosin alpha-1 is in an awkward tier position: it's an actual approved drug in roughly 35 countries (Zadaxin, marketed by SciClone), with decades of clinical trial data for specific indications, especially chronic hepatitis B adjunct therapy and selected immune-adjacent settings. Sepsis, HCV, and oncology signals are mixed or context-specific. The problem for a grey-market tier list is that almost none of the peptide-community usage is for those approved indications. It's sold as a generic 'immune booster' for anything from chronic fatigue to COVID recovery. The on-label evidence is real. The off-label community use the compound is actually being purchased for is much thinner.

what it is

thymosin alpha-1 is a 28-amino-acid n-terminally acetylated peptide naturally produced by the thymus gland and identified by allan goldstein's group in 1977. synthetic version commercialized as Zadaxin by sciclone. modulates t-cell maturation and dendritic cell activity. plasma half-life around two hours. the approved-use story is abroad and indication-specific, not a U.S. generic immune-booster lane.

what it does

immunomodulator. clinically used in roughly 35 countries as adjunct therapy for chronic hepatitis b, with weaker evidence in hepatitis c and some oncology contexts. the etass sepsis trial out of china in 2013 suggested a 28-day mortality benefit. newer literature is drifting into immunosenescence and pd-1 combination work in oncology.

origin

isolated from thymus gland extract in the 1970s, sequenced in 1977. sciclone developed and commercialized it as Zadaxin starting in the late 1990s. approved across italy, china, mexico, and roughly 30 other countries for hepatitis b and c. multiple fda approval attempts in the us never succeeded, leaving it in a permanent regulatory middle ground that almost no other peptide occupies.

why researchers are interested

clean safety profile across decades of approved use. modest but consistent reports from users with documented immune dysregulation, chronic infections, autoimmune flares, post-viral syndromes. healthy users tend to report less, which is exactly what immunomodulators should do. sold as a monthly package by us compounding pharmacies, and cheaper on the research-chemical market.

does it work

for chronic hep b adjunct, yes, the evidence is solid and the approvals abroad are real. but the larger sepsis story has weakened: the TESTS phase 3 trial (n=1,106, BMJ 2025) missed its primary 28-day mortality endpoint (23.4% vs 24.1% placebo, HR 0.99), with subgroup signals favoring older and diabetic patients. Ciancio 2012 in HCV retreatment was already negative. The Dec 4, 2024 FDA PCAC voted AGAINST 503A inclusion (after the nominator withdrew in Sept 2024), effectively closing the US compounded-pharmacy pathway. For the way the US peptide community actually uses it (generic immune support, long covid, chronic fatigue), the trial base is just extrapolation. The 2025 HCC retrospective (Tα1 + lenvatinib + sintilimab) showed real survival signal as immunotherapy adjunct (median OS 16 vs 11 months) - that's the live frontier.

claims vs the data

  • approved for chronic hepatitis B as an adjunct to standard therapy — supported — Approved in multiple countries since the late 1990s, with clinical trial evidence establishing benefit as adjunct to interferon-based protocols. This is the most substantial evidence base for the peptide.
  • improves outcomes in chronic hepatitis C — partially true — Some trials in combination with interferon/ribavirin protocols showed benefit, though the landscape has been largely overtaken by modern direct-acting antivirals that no longer require thymosin adjunct therapy.
  • boosts immunity against infections generally — weak — Community marketing position, but the clinical evidence base is for specific immune-compromised or specific-viral contexts, not for general immune support in healthy individuals. Extrapolation well beyond the approved indications.
  • useful for cancer immunotherapy adjunct — partially true — Trial data exists in some oncology contexts (melanoma, hepatocellular carcinoma) with mixed results. Not a first-line cancer immunotherapy under current standards.
  • effective for long COVID and chronic fatigue — unverified — Current popular community use case with no rigorous trial data. Reflects extrapolation from the general 'immune support' framing rather than specific evidence.
  • clean safety profile in approved-use settings — supported — Long clinical track record across multiple countries and decades shows a clean safety profile in the studied and approved contexts.
  • thymosin alpha-1 is a general immune booster — overreach — The credible record is condition-specific: hepatitis programs, sepsis trials, COVID-era studies, and oncology-adjacent immune contexts. That does not translate cleanly into a broad wellness immune-boosting claim.

key facts

  • molecular formula: C129H215N33O55
  • molecular weight: 3108.3 Da
  • amino acids: 28
  • half-life: approximately 2 hours in plasma (subcutaneous); dosing regimens typically twice weekly in approved indications
  • type: 28 amino acid N-terminally acetylated peptide
  • CAS: 62304-98-7
  • ~35 countries where approved (Zadaxin)
  • 0 FDA approvals in US
  • 1977 year identified and sequenced
  • chronic HBV adjunct primary approved indication

frequently asked questions

What is thymosin alpha-1?

Thymosin alpha-1 (Tα1) is a 28-amino-acid peptide naturally produced by the thymus gland. Isolated and synthesized by Allan Goldstein's group in the 1970s, it plays a central role in T-cell maturation and immune regulation.

What does thymosin alpha-1 do?

Thymosin alpha-1 modulates T-cell function and broader immune response. It is clinically used in multiple countries for chronic hepatitis B, chronic hepatitis C, and immune support in sepsis and cancer treatment. Community users target general immune support during illness or post-infection recovery.

How is thymosin alpha-1 typically administered?

Approved international use is injectable and indication-specific, most notably Zadaxin-style hepatitis protocols outside the United States. There is no FDA-approved U.S. dosing framework for generic immune support, long COVID, chronic fatigue, or wellness use.

What are the side effects of thymosin alpha-1?

Side effect profile is notably clean. Occasional injection-site reactions, mild flu-like symptoms during initial doses (reflecting immune activation), and rare transient fatigue. Long-term safety data from hepatitis treatment programs supports a favorable tolerability profile.

Is thymosin alpha-1 FDA approved?

No in the United States. Thymosin alpha-1 (branded as Zadaxin) is approved in 35+ countries, primarily around chronic hepatitis B and selected immune-adjacent settings, but it does not have FDA approval. FDA's PCAC voted against placing thymosin alpha-1 forms on the 503A bulks list, so routine U.S. compounding is not a clean lane.

How much does thymosin alpha-1 cost?

No US clinical retail. Compounded thymosin alpha-1 from hormone clinics is sold as a monthly package. On the research-chemical market it is cheaper than the clinic route.

related peptides

  • kpv — anti-inflammatory peptide with overlapping immune positioning
  • bpc-157 — healing/immune-adjacent peptide with stronger community track record
  • hcg — another approved peptide with significant grey-market off-label use

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.